Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02932358
Other study ID # ICU Visits
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 28, 2017
Est. completion date June 22, 2018

Study information

Verified date November 2018
Source Hospital Moinhos de Vento
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A cluster-randomized crossover trial involving adult ICU patients, family members, and ICU professionals will be conducted. Forty medical-surgical Brazilian ICUs with visiting hours <4.5 h/day will be randomly assigned to either a restrictive family visitation model (RFVM) (visits according to local policies) or a flexible family visitation model (FFVM) (visitation during 12 consecutive hours per day) at a 1:1 ratio. After enrollment and follow-up of 25 patients, each ICU will be switched over to the other visitation model, until 25 more patients per site are enrolled and followed. The primary outcome will be the cumulative incidence of delirium among ICU patients, measured twice a day using the Confusion Assessment Method for the ICU. Secondary outcome measures will include daily hazard of delirium, ventilator-free days at day 7, any ICU-acquired infections, ICU length of stay, and all-cause hospital mortality among the patients; symptoms of anxiety and depression and satisfaction among the family members; and prevalence of symptoms of burnout among the ICU professionals. Tertiary outcomes will include need for antipsychotic agents and/or mechanical restraints, coma-free days at day 7, unplanned loss of invasive devices, and ICU-acquired pneumonia, urinary tract infection, or bloodstream infection among the patients; self-perception of involvement in patient care among the family members; and satisfaction among the ICU professionals.


Recruitment information / eligibility

Status Completed
Enrollment 1650
Est. completion date June 22, 2018
Est. primary completion date June 22, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- For ICUs: medical-surgical ICUs of of public and philanthropic Brazilian hospitals with restricted visitation policies(<4.5 hours/day).

- For Patients: Age = 18 years, admission to the intensive care unit.

- For Patient's Family Members: nearest relative of the ICU patient recruited in the study and consent to participate in the study.

- For ICU Workers: ICU workers that assist patients in the ICU during the daytime for at least 20 hours per week and consent to participate in the study.

Exclusion Criteria:

- For ICUs: ICUs with structural or organizational impediments to extended visitation.

- For Patients: Subjects with coma (Richmond Agitation Sedation Scale -4 or -5) lasting > 96 hours from the moment of first evaluation for recruitment, or delirium at the baseline (positive Confusion Assessment Method for ICU) will be excluded. Individuals with cerebral death, aphasia, severe hearing deficit, a prediction of ICU length of stay < 48 hours, exclusively palliative treatment, or without a familiar member able to participate in extended ICU visits and those who are prisioners, unlikely to survive >24hs, re-admitted to the ICU after enrolment in the study will also be excluded.

- For Patient's Family Members: Another ICU patient's relative enrolled in the study; family members who don't speak Portuguese; Difficulty to answer the self-administered questionnaires (e.g.: illiteracy)

- For ICU Workers: ICU workers who have a prediction of withdrawal of ICU care activities >15 days during the study will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Flexible Family Visitation Model (FFVM)
Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
Restrictive Family Visitation Model (RFVM)
Visitation to ICU patients allowed during intermittent periods according local ICU regulation.

Locations

Country Name City State
Brazil Hospital das Clínicas da Universidade Federal de Minas Gerais Belo Horizonte MG
Brazil Hospital Tacchini Bento Gonçalves RS
Brazil Hospital Universitário Alcides Carneiro Campina Grande PB
Brazil Hospital do Caâncer de Cascavel (UOPECCAN) Cascavel PR
Brazil Hospital Universitário do Oeste do Paraná (UNIOESTE) Cascavel PR
Brazil Hospital São Camilo de Esteio Esteio RS
Brazil Hospital Geral Clériston Andrade Feira De Santana BA
Brazil Hospital INCARDIO Feira De Santana BA
Brazil Hospital de Urgências de Goiânia Goiânia Goias
Brazil Hospital Alberto Urquiza Wanderley (UNIMED João Pessoa) João
Brazil Hospital Universitário Lauro Wanderley João Pessoa PB
Brazil Hospital Dona Helena Joinville SC
Brazil Fundação Hospital Adriano Jorge Manaus AM
Brazil Hospital Montenegro Montenegro
Brazil Hospital Geral de Nova Iguaçú Nova Iguaçú RJ
Brazil Hospital Deoclécio Marques de Lucena Parnamirim RN
Brazil Hospital da Cidade de Passo Fundo Passo Fundo RS
Brazil Hospital Universitário de Petrolina Petrolina PE
Brazil Hospital de Clínicas de Porto Alegre Porto Alegre RS
Brazil Hospital Dom Vicente Scherer Porto Alegre RS
Brazil Hospital Mãe de Deus Porto Alegre RS
Brazil Hospital Nossa Senhora da Conceiçaão Porto Alegre RS
Brazil Hospital Santa Rita Porto Alegre RS
Brazil Pavilhão Pereira Filho Porto Alegre RS
Brazil Hospital Agamenom Magalhães Recife PE
Brazil Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Ribeirão Preto SP
Brazil Hospital de Urgência e Emergência de Rio Branco Rio Branco AC
Brazil Hospital Ana Nery Santa Cruz Do Sul RS
Brazil Hospital Santa Cruz Santa Cruz Do Sul RS
Brazil Hospital Regional do Baixo Amazonas Santarém PA
Brazil Santa Casa de Misericórdia de São João Del Rei São João Del Rei MG
Brazil Hospital do Coração (HCor) São Paulo SP
Brazil Hospital Universitário da Universidade Federal do Piauí Teresina PI

Sponsors (2)

Lead Sponsor Collaborator
Hospital Moinhos de Vento Ministry of Health, Brazil

Country where clinical trial is conducted

Brazil, 

References & Publications (2)

Rosa RG, Falavigna M, Robinson CC, da Silva DB, Kochhann R, de Moura RM, Santos MMS, Sganzerla D, Giordani NE, Eugênio C, Ribeiro T, Cavalcanti AB, Bozza F, Azevedo LCP, Machado FR, Salluh JIF, Pellegrini JAS, Moraes RB, Hochegger T, Amaral A, Teles JMM, da Luz LG, Barbosa MG, Birriel DC, Ferraz IL, Nobre V, Valentim HM, Corrêa E Castro L, Duarte PAD, Tregnago R, Barilli SLS, Brandão N, Giannini A, Teixeira C; ICU Visits Study Group Investigators and the BRICNet. Study protocol to assess the effectiveness and safety of a flexible family visitation model for delirium prevention in adult intensive care units: a cluster-randomised, crossover trial (The ICU Visits Study). BMJ Open. 2018 Apr 13;8(4):e021193. doi: 10.1136/bmjopen-2017-021193. — View Citation

Sganzerla D, Teixeira C, Robinson CC, Kochhann R, Santos MMS, de Moura RM, Barbosa MG, da Silva DB, Ribeiro T, Eugênio C, Schneider D, Mariani D, Jeffman RW, Bozza F, Cavalcanti AB, Azevedo LCP, Machado FR, Salluh JI, Pellegrini JAS, Moraes RB, Damiani LP, da Silva NB, Falavigna M, Rosa RG. Statistical analysis plan for a cluster-randomized crossover trial comparing the effectiveness and safety of a flexible family visitation model for delirium prevention in adult intensive care units (the ICU Visits Study). Trials. 2018 Nov 19;19(1):636. doi: 10.1186/s13063-018-3006-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Delirium among ICU patients Incidence of delirium will be verified by trained intensive care professionals with the confusion assessment method for the ICU 2 times per day. During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary Daily hazard of delirium among ICU patients The daily hazard of delirium will be analyzed using a joint survival model that accounts for the treatment effect on repeated daily indicator of delirium (Confusion Assessment Method for the ICU) within each patient and terminating event (death or discharge from the ICU). During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary Antipsychotic use among ICU patients Need of antipsychotic use during ICU stay During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary Need of mechanical restraints among ICU patients Need of mechanical restraints among ICU patients during ICU stay During ICU stay (from randomization until ICU discharge, or death, or a maximum of 30 days of follow-up)
Secondary Coma-free days at day 7 among ICU patients Days alive and free of coma (Richmond Agitation Sedation Scale -4 or -5) during ICU stay. During the first 7 days following patient enrollment.
Secondary Unplanned loss of invasive devices among ICU patients Unplanned loss of venous catheter, tube feeding or urinary catheter During ICU stay (from randomization until ICU discharge, or death, or a maximum of 30 days of follow-up)
Secondary Mechanical ventilation-free days at day 7 among ICU patients Days alive and free of mechanical ventilation during ICU stay. During the first 7 days following patient enrollment.
Secondary Any ICU-acquired infection among ICU patients Pneumonia or bloodstream infection or urinary tract infection acquired after 48 hours of ICU admission. During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary ICU-acquired pneumonia among ICU patients Pneumonia acquired after 48 hours of ICU admission. During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary ICU-acquired bloodstream infection among ICU patients Bloodstream infection acquired after 48 hours of ICU admission. During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary ICU-acquired urinary tract infection among ICU patients Urinary tract infection acquired after 48 hours of ICU admission. During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary ICU length of stay among ICU patients Length of ICU stay in days During ICU stay (from enrollment until ICU discharge, or death or a maximum of 30 days of follow-up)
Secondary All-cause hospital mortality among ICU patients rates of all-cause mortality during hospital stay During hospital stay (from enrollment until hospital discharge, or death or a maximum of 30 days of follow-up)
Secondary Symptoms of anxiety among family members symptoms of anxiety among family members measured by the Hospital Anxiety and Depression scale IOn the day of patient discharge from ICU, or death or a maximum of 30 days of follow-up.
Secondary Symptoms of depression among family members symptoms of depression among family members measured by the Hospital Anxiety and Depression scale On the day of patient discharge from ICU, or death or a maximum of 30 days of follow-up.
Secondary Satisfaction among among family members Rates of patient's families satisfaction measured by the critical care family needs inventory On the day of patient discharge from ICU, or death or a maximum of 30 days of follow-up.
Secondary Prevalence of Burnout Syndrome among ICU professionals Prevalence of Burnout Syndrome among ICU workers measured by the Maslach Burnout Inventory It will be measured in two moments: within 15 days prior to the first ICU intervention and between the 15th and 30th days of the period in which no patient will be enrolled.
Secondary Satisfaction with the current ICU visiting policy among ICU professionals Satisfaction with the current ICU visiting policy among ICU professionals It will be measured between the 15th and 30th days of the period in which no patient will be enrolled.
Secondary Any adverse event related to ICU visitation Any adverse event possible related to the ICU visitation model During ICU stay (from randomization until ICU discharge, or death, or a maximum of 30 days of follow-up)
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT05891873 - Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Recruiting NCT06194474 - Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
Completed NCT03095417 - Improving the Recovery and Outcome Every Day After the ICU N/A
Completed NCT05395559 - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Terminated NCT03337282 - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Not yet recruiting NCT04846023 - Pediatric Delirium Screening in the PICU Via EEG N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Withdrawn NCT02673450 - PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
Recruiting NCT03256500 - Transcranial Direct Current Stimulation for the Treatment of Delirium N/A
Not yet recruiting NCT02892968 - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients N/A
Completed NCT02890927 - Geriatric-CO-mAnagement for Cardiology Patients in the Hospital N/A
Recruiting NCT03165539 - Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
Completed NCT02518646 - DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models N/A
Completed NCT02554253 - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction Phase 2
Recruiting NCT02305589 - The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium N/A
Completed NCT02628925 - Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale N/A